Endocare, Inc.
HCID Member | Medical Devices & Tech  Advamed Member
201 Technology Drive
Irvine, CA 92618 USA
phone: 949-450-5400
fax: 949-450-5300
Symbol ENDO
Exchange NASDAQ
Founded 1990
Employees 117
www.endocare.com
Research Sector Medical Devices & Tech
Summary Description
Diagnostic technology for the identification of prostate abnormalities, including prostate cancer
Management
Terrence A. Noonan, Director, Interim CEO & Interim President

Michael Rodriguez, CFO
Ownership
Financials Mkt Cap :11


* numbers in thousands

 
Keywords
cancer, urological, surgery products, urology, prostate, urinary, bladder, erectile, advamed, cryotherapy, renal, pain, management, ablation, kidney, liver, lung, cryoablation, minimally invasive, metastases, palliative intervention

Comment | Printable Version | Nov. 01, 2008
If you work for Endocare, Inc. and want to update this profile, click here

Description
Endocare, Inc. is focused on cryoablation technology for minimally invasive treatment of prostate and renal cancer, developing tumors in the kidneys, lungs, and liver, and for palliative intervention (pain relief) for metastases. The company's operations are fully integrated, from R&D to manufacturing to marketing and direct sales.
Products / Services
Cryocare CS treats prostate and renal cancer, as well as simplifies TCAP (Targeted Cryoablation of the Prostate) procedures.
Technology / Differentiation
One key element of the FDA-cleared Cryocare CS system is the AutoFreeze, a computer-controlled automated freezing mechanism that utilizes optimal power settings based upon target endpoint temperatures and continual feedback from the thermocouple tips. Along with AutoFreeze, Cryocare CS includes new Integrated Ultrasound technology that provides internal visualization of the prostate gland and patented CryoGuide planning software that assists physicians in determining optimal treatment of the entire gland.
Market / Customers
Endocare's cryoablation technology platforms are marketed and sold by a direct-sales force to urologists and interventional radiologists. To date, the majority of sales have been to physicians for medium to high-risk prostate and renal cancer patients. However, the company's technologies have broader applications, including ablation of tumors in the kidney, lung, and liver, and for palliative intervention (pain relief) for metastases.
Competitors / Substitutes / Alternatives
Endocare's proprietary technologies and brands, trademarks and tradenames are protected by more than ninety U.S. and foreign patents and patents pending. Still, significant competitors in the area of prostate cancer and other tumor ablation (renal, liver, lung, palliative intervention) include companies that offer: surgical devices (such as robotic surgery equipment); brachytherapy seeds and other forms of radiation therapy; and ablation products, including cryoablation products and radiofrequency ablation (RFA) products. Other devices in development, such as high intensity focused ultrasound (HIFU), microwave and others, may become competitive devices in the future.
Strategy
The company will continue to penetrate urology, interventional radiology and oncology markets and migrate to device manufacturing and sales. The focus on disposables and increasing product utilization via higher awareness of cryoablation and its comparative benefits is a core strategy, as is eliminating service component of business. Endocare seeks to develop new markets for cryosurgical products and technologies, particularly in tumor ablation.
Status
Endocare unveiled the next generation of its cryotherapy technology, the Cryocare CS. This system is fully integrated and provides planning, placement and treatment options to simplify the FDA-cleared Targeted CryoAblation of the Prostate (TCAP) procedure.


2008-11-22-5182